Lower COVID-19 Vaccine Sales Estimated Amid Less Severe Omicron Variant: Bloomberg

Loading...
Loading...

According to an analytics firm, Airfinity Ltd, evidence that omicron causes less-severe disease than earlier COVID-19 variants is expected to lower the growth in vaccine sales this year.

  • Citing Airfinity, Bloomberg reports that COVID-19 vaccine sales, excluding China and India, will increase to about $85 billion in 2022, down about 28% from an earlier estimate of $118 billion.
  • The analytics firm said that the revision was also due to lower prices paid by poorer nations for the shots.
  • Related: Federal Health Officials Say Omicron-Targeted Shots May Not Be Necessary: WSJ.
  • Demand for doses is still rising, and booster programs in high-income countries will be a key driver, according to Airfinity, which estimates that sales will climb almost 30% in 2022 from about $66 billion last year. 
  • Moderna Inc MRNA could record about $26 billion in sales in 2022, while Pfizer Inc PFE and its partner BioNTech SE BNTX may clock about $43 billion. 
  • AstraZeneca Plc AZN is expected to generate $4.3 billion in vaccine revenue. 
  • The firm's estimates differ from that of the drugmakers themselves. 
  • Pfizer has forecast $31 billion in 2022 COVID-19 vaccine sales. 
  • Prelim COVID-19 vaccine sales for Moderna stand at $18.5 billion, along with a potential $3.5 billion from boosters and other purchases. 
  • Price Action during the premarket session on the last check Friday:
    • MRNA stock is down 1.27% at $165.40 
    • PFE shares are down 0.30% at $53.89 
    • BNTX stock is down 2.15% at $153.16 
    • AZN shares are down 0.48% at $59.88 
Loading...
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...